Find us on:


Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis

Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis
Publication Type
Book Chapter
Research Type
Reported as
November 27, 2017
Ian S. Zagon, Patricia J. McLaughlin
Pennsylvania State University

Endogenous opioids are enkephalins and endorphins that are primarily produced in the brain and have multiple actions throughout the body. Enkephalins and endorphins act at opioid receptors and their activity can be blocked by opioid antagonists. A small pentapeptide termed opioid growth factor (OGF), and chem-ically termed [Met5]-enkephalin, has been shown to have causative and therapeu-tic roles in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). Enkephalin levels are reduced in animals and humans during MS relapses, and may play a role in etiology. Exogenous therapy with OGF or endogenous stimulation of OGF by low dosages of naltrexone (LDN) reverse the course of progressive EAE and limit the number of relapses in relapsing- remitting EAE. Individuals prescribed LDN report less fatigue and a better quality of life while using LDN. This chapter summarizes the information from studies using two different animal models of EAE, as well as two different treatment regi-mens of two different compounds—OGF or LDN. In all investigations, the pres-ence of enkephalins resulted in beneficial effects.